BioMarin Q1 revenue up 3% to $766M; EPS down; raises FY2026 guidance to $3.825-$3.925B

BIOMARIN PHARMACEUTICAL INC

2026-Q1 EPS reported $0.54 revenue$766,208,000

Total revenues $766M (+3% YoY); GAAP net income $106M (down 43%) vs $186M.
GAAP diluted EPS $0.54 vs $0.95; non-GAAP diluted EPS $0.76 vs $1.13.
FY2026 revenue guidance raised to $3.825B-$3.925B, implying ~20% YoY growth at midpoint.
Operating cash flow $221M; closed $3.7B non-convertible debt to fund Amicus acquisition.
Enzyme Therapies revenue up 6% to $514M; VOXZOGO $220M (+3%); $31M charge for NAGLAZYME campaign.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BIOMARIN PHARMACEUTICAL INC reported the first quarter ended March 31, 2026 results: revenue $766 million, net income $106 million. Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: $766 million
Net income: $106 million
Guidance: raised
Result: reported results

Exact text from the filing

Total Revenues for the first quarter of 2026 were $766 million

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

BIOMARIN PHARMACEUTICAL INC filing history →

Source: SEC EDGAR

accession 0001048477-26-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.